Using NanoString PanCancer Immuno-Oncology 360TM molecular profiles derived from patient tumor samples in conjunction with NSA, we identified that high expression of ENTPD1/CD39 was associated with a significant and independent improvement in OS and RFS with Vigil maintenance therapy in the VITAL study. The gene discussed is ENTPD1; the disease is neoplasm.